Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis
Üstün, Celalettin , Reiter, Andreas , Scott, Bart L. , Nakamura, Ryotaro , Damaj, Gandhi , Kreil, Sebastian, Shanley, Ryan , Baurmann, H., Doubek, Michael , Hsu, Jack W., Tholouli, Eleni , Gromke, Tanja , Godley, Lucy A. , Pagano, Livio , Gilman, Andrew L. , Wagner, Eva , Shwayder, Tor , Papadopoulos, Esperanza B. , Böhm, Alexandra, Vercellotti, Gregory M. , Lint, Maria Teresa Van, Rabitsch, Werner , Pullarkat, Vinod , Legrand, Faézeh, Yakoub‐Agha, Ibrahim , Saber, Wael , Barrett, J. Carl, Hermine, Olivier , Hägglund, Hans , Sperr, Wolfgang R. , Alyea, Edwin P. , Deeg, H. Joachim , Weisdorf, Daniel J. , Akin, Cem , Valent, Peter , Shore, Tsiporah, Baurmann, Herrad, Stuart, Robert, Gruhn, Bernd, Gilman, Andrew, Wagner, Eva Maria, Bornhäuser, Martin, Vercellotti, Gregory, Van Lint, Maria Teresa, Schmid, Christoph, Yakoub-Agha, Ibrahim, Barrett, John , Popat, Uday, Devine, Steven, Weisdorf, Daniel, Hogan, William J. , Perales, Miguel‐Angel , Shore, Tsiporah B. , Stuart, Robert K. , Gruhn, Bernd , Bornhäuser, Martin , Schmid, Christoph , Popat, Uday R , Devine, Steven M. , Weisdorf, Dan , Sperr, Wolfgang , Valent, Peter , Yakoub-Agha, Ibrahim , Hermine, Olivier , Akin, Cem , Godley, Lucy A

Journal of Clinical Oncology | August 26, 2014 | Volume: 32 | Issue: 29 | Pages: 3264-3274

10.1200/jco.2014.55.2018 | PMID 25154823 Get It

PurposeAdvanced systemic mastocytosis (SM), a fatal hematopoietic malignancy characterized by drug resistance, has no standard therapy. The effectiveness of allogeneic hematopoietic stem-cell transplantation (alloHCT) in SM remains unknown.Patients and MethodsIn a global effort to define the value of HCT in SM, 57 patients with the following subtypes of SM were evaluated: SM associated with clonal hematologic non–mast cell disorders (SM-AHNMD; n = 38), mast cell leukemia (MCL; n = 12), and aggressive SM (ASM; n = 7). Median age of patients was 46 years (range, 11 to 67 years). Donors were HLA-identical (n = 34), unrelated (n = 17), umbilical cord blood (n = 2), HLA-haploidentical (n = 1), or unknown (n = 3). Thirty-six patients received myeloablative conditioning (MAC), and 21 patients received reduced-intensity conditioning (RIC).ResultsResponses in SM were observed in 40 patients (70%), with complete remission in 16 patients (28%). Twelve patients (21%) had stable disease, and five patients (9%) had primary refractory disease. Overall survival (OS) at 3 years was 57% for all patients, 74% for patients with SM-AHNMD, 43% for those with ASM, and 17% for those with MCL. The strongest risk factor for poor OS was MCL. Survival was also lower in patients receiving RIC compared with MAC and in patients having progression compared with patients having stable disease or response.ConclusionAlloHCT was associated with long-term survival in patients with advanced SM. Although alloHCT may be considered as a viable and potentially curative therapeutic option for advanced SM in the meantime, given that this is a retrospective analysis with no control group, the definitive role of alloHCT will need to be determined by a prospective trial.
Evaluation of the Effect of Decision Support on the Efficiency of Primary Care Providers in the Outpatient Practice
Hankey, Ronald A., Decker, Lindsay K. , Cha, Stephen S., Greenes, Robert A. , Chaudhry, Rajeev , Wagholikar, Kavishwar B. , Cha, Stephen S., Liu, Hongfang

Journal of Primary Care & Community Health | August 26, 2014 | Volume: 6 | Issue: 1 | Pages: 54-60

10.1177/2150131914546325 | PMID 25155103 Get It

Background: Clinical decision support (CDS) for primary care has been shown to improve delivery of preventive services. However, there is little evidence for efficiency of physicians due to CDS assistance. In this article, we report a pilot study for measuring the impact of CDS on the time spent by physicians for deciding on preventive services and chronic disease management. Methods: We randomly selected 30 patients from a primary care practice, and assigned them to 10 physicians. The physicians were requested to perform chart review to decide on preventive services and chronic disease management for the assigned patients. The patients assignment was done in a randomized crossover design, such that each patient received 2 sets of recommendations—one from a physician with CDS assistance and the other from a different physician without CDS assistance. We compared the physician recommendations made using CDS assistance, with the recommendations made without CDS assistance. Results: The physicians required an average of 1 minute 44 seconds, when they were they had access to the decision support system and 5 minutes when they were unassisted. Hence the CDS assistance resulted in an estimated saving of 3 minutes 16 seconds (65%) of the physicians’ time, which was statistically significant ( P < .0001). There was no statistically significant difference in the number of recommendations. Conclusion: Our findings suggest that CDS assistance significantly reduced the time spent by physicians for deciding on preventive services and chronic disease management. The result needs to be confirmed by performing similar studies at other institutions.
The Effect of Information Presentation on Beliefs About the Benefits of Elective Percutaneous Coronary Intervention
Scherer, Laura D. , Kashef, Mohammad Amin, Coylewright, Megan , Ting, Henry H. , Zikmund‐Fisher, Brian J. , Rothberg, Michael B. , Hu, Bo

JAMA Internal Medicine | August 25, 2014 | Volume: 174 | Issue: 10 | Pages: 1623

10.1001/jamainternmed.2014.3331 | PMID 25156687 Get It

Skepticism should not result in ignoring a treatment option
Helmers, Sandra L., Hirsch, Lawrence J. , Sirven, Joseph I , Vale, Fernando Ĺ. , Benbadis, Selim, Helmers, Sandra, Hirsch, Lawrence, Sirven, Joseph, Wheless, James, Benbadis, Selim R. , Wheless, James W. , Hirsch, Lawrence J

Neurology | August 25, 2014 | Volume: 83 | Issue: 9 | Pages: 849-850

10.1212/wnl.0000000000000743 | PMID 25156351 Get It

Yes, neurostimulation has a role in the management of epilepsy
Helmers, Sandra L., Hirsch, Lawrence J. , Sirven, Joseph I , Vale, Fernando Ĺ. , Benbadis, Selim, Helmers, Sandra, Hirsch, Lawrence, Sirven, Joseph, Wheless, James, Benbadis, Selim R. , Wheless, James W. , Hirsch, Lawrence J

Neurology | August 25, 2014 | Volume: 83 | Issue: 9 | Pages: 845-847

10.1212/wnl.0000000000000739 | PMID 25156348 Get It

How does deep brain stimulation work?
Agnesi, Filippo , Baker, Kenneth B. , Vitek, Jerrold L.

Deep Brain Stimulation: Technology and Applications (Volume 1) | August 25, 2014 | Volume: No volume available | Issue: No issue available | Pages: 104-119

10.2217/ebo.13.564 Get It

How Cardiologists Present the Benefits of Percutaneous Coronary Interventions to Patients With Stable Angina
Goff, Sarah L. , Mazor, Kathleen M. , Ting, Henry H. , Kleppel, Reva, Rothberg, Michael B.

JAMA Internal Medicine | August 25, 2014 | Volume: 174 | Issue: 10 | Pages: 1614

10.1001/jamainternmed.2014.3328 | PMID 25156523 Get It

Liver transplantation for hepatopulmonary syndrome
Iyer, Vivek

Clinical Liver Disease | August 25, 2014 | Volume: 4 | Issue: 2 | Pages: 38-41

10.1002/cld.412 | PMID 30992918 Get It

Estimating survival of patients receiving radiosurgery alone for cerebral metastasis from melanoma
Sehmisch, Lena, Huttenlocher, Stefan , Rades, Dirk , Schild, Steven E.

The Journal of Dermatology | August 25, 2014 | Volume: 41 | Issue: 10 | Pages: 918-921

10.1111/1346-8138.12599 | PMID 25154301 Get It

AbstractThis study aimed to identify clinical factors associated with survival and to develop a prognostic tool in patients receiving radiosurgery alone for very few cerebral metastases from melanoma. Ten characteristics of 69 patients treated with radiosurgery alone for 1–3 cerebral metastases from melanoma were retrospectively analyzed for survival. Serum lactate dehydrogenase levels before radiosurgery, Karnofsky performance score, maximum diameter of all irradiated cerebral lesions, and extracranial lesions were significantly associated with survival and included in the tool. Twelve‐month survival rate (in %) divided by 10 was calculated for each of these four factors. The four scores were summed resulting in total scores ranging 9–22 points. Based on the 12‐month survival rates, three groups were formed: less than 15 points (group I, n = 25); 15–20 points (group II, n = 34); and more than 20 points (group III, n = 10). Corresponding 12‐month survival rates were 10 ± 6%, 51 ± 9% and 90 ± 9%, respectively (P < 0.001). In group I, death within 12 months following radiosurgery occurred mostly due to extracranial progression, whereas cerebral progression was the major cause of death in group II. In group III, only one of 10 patients died within 1 year. This new prognostic tool helps predict the survival time following radiosurgery of very few cerebral metastases from melanoma. An individual treatment approach should consider a patient's survival time and the most likely cause of death (cerebral or extracranial progression).
The Effect of CYP2D6 Drug-Drug Interactions on Hydrocodone Effectiveness
Monte, Andrew A. , Heard, Kennon , Campbell, Jenny A., Hamamura, D., Weinshilboum, Richard M. , Vasiliou, Vasilis , Weinshilboum, Richard M.

Academic Emergency Medicine | August 24, 2014 | Volume: 21 | Issue: 8 | Pages: 879-885

10.1111/acem.12431 | PMID 25156930 Get It